How long should we treat primary osteoporosis?
|
|
- Meryl Allen
- 6 years ago
- Views:
Transcription
1 Earn 3 CPD Points online Current Osteoporosis management With a FOCUS on ideal length of treatment and considerations in the use of menopausal hormone therapy for fracture prevention Dr Tobie De Villiers Consultant Gynaecologist Panorama MediClinic Department of Obstetrics and Gynaecology Stellenbosch University Past President, International Menopause Society Introduction This CPD Accredited report from the 16th congress of the National Osteoporosis Foundation of South Africa (NOFSA) held on October 2014 at the Wanders Club, Sandton, South Africa, focusses on two review topics. Firstly, the ideal treatment time for Primary Osteoporosis that will ensure protection from fractures in the individual patient and secondly, clinical aspects concerning the use of Menopausal hormone therapy with regard to its use in osteoporosis. These topics are directed at everyday clinical practice by Dr Tobie De Villiers, Specialist, Cape Town. How long should we treat primary osteoporosis? KEY MESSAGES This article was made possible by an unrestricted educational sponsorship from MSD, which had no control over content In considering the length of treatment, the clinician must evaluate the efficacy, safety and pharmacokinetics of the specific drug in the context of the individual patient s risk, response and adherence to therapy Menopausal hormone therapy prevents bone loss and fractures at any age, but benefit is more likely to outweigh risks when initiated in the first 10 years after menopause or before age 60 years Combination of estrogen and progestogen may be associated with the promotion of pre-existing breast cancer after 7 years and with estrogen alone therapy after 10 years Raloxifene has been shown to be effective for 3-5 years but has no specific limitation on duration of use Teriparatide use is restricted to a period of months Strontium ranelate has been shown to be efficient in the prevention of fractures over 10 years. Although there is no specific limitation placed on duration of treatment, older patients may be at increased risk of cardiovascular risk. Strontium ranelate is contraindicated in the patient at increased cardiovascular risk Bisphosphonates used for periods longer than 3-5 years may be associated with ONJ and AFF, but the benefit to risk ratio is still very favorable. Bisphosphonates bind tightly to bone and have a residual effect when stopped. A drug holiday can be considered after 3-5 years in patients at low risk of fracture after treatment In all instances where therapy with a particular agent is discontinuated and fracture risk remains significant, alternative therapies should be instituted. The question of the length of treatment with bone specific medications for the prevention of fractures in individuals with osteoporosis remains a much debated and controversial issue, Dr Tobie de Villiers pointed out. There are however useful principles which can aid the clinician in his decision making for an individual patient approach. JANUARY
2 We are fortunate to have a selection of drugs for treating patients with primary osteoporosis, each with their own recommended period for treatment. Earn 3 CPD points at Click on Accredited Education Programmes/CPD Menopausal hormone therapy (HT) HT is indicated for the prevention of bone loss and fractures in postmenopausal women at risk if initiated before the age of 60 years or within 10 years of menopause. The lengh of treatment is not subject to mandatory timelines but should be guided by the indication for treatment. The only safety issue related to duration of treatment is the promotion of preexisting breast cancer. When using estrogen alone therapy, this is not applicable in the first 10 years of therapy. When using combination of estrogen and progestogen, in the treatment naïve patient, this is not applicable in the first 7 years of treatment. On discontinuation of HT, bone mineral density (BMD) reverts to baseline mostly within one year with the possibility of some degree of down-stream protection. On stopping HT, other anti-osteoporotic agents should be used if the patient is still at risk of fractures. Raloxifene Raloxifene has been shown to be effective for 5 years without specific complications, but should be used with caution in patients at risk of stroke. Unlike HT, the risk of estrogen receptor positive breast cancer is decreased with the use of raloxifene. Cessation of this agent results in loss of BMD to baseline levels within 1 year and other agents should be considered for atrisk women. Teriparatide for severe osteoporosis This recombinant human parathyroid hormone is the only pure bone anabolic agent presently available and is reserved for severe osteoporosis. It has a very narrow therapeutic window of months. After this period an increase in bone resorption occurs and the anabolic effect is lost. Termination of therapy with this agent must be followed by other anti-resportive therapy. Strontium ranelate Fracture efficacy has been established over 10 years in a study and there were no specific safety issues during this period. Older patients are at greater risk for CVD and VTE s and this aspect must be taken into consideration. Bisphosphonates The bisphosphonates are still the most widely used drugs for the prevention of post menopausal fractures. Bisphosphonates present different challenges when considering length of treatment`; 1. Safety aspects related to duration of use Osteonecrosis of the jaw (ONJ) is defined as exposed bone without healing after 8 weeks following a dental procedure. ONJ is extremely rare at the dosages of bisphosphonates used for fracture protection and is more commonly related to much higher dosages of bisphosphonates as used in oncology Atypical fractures of the femur shaft (AFF) Bisphosphonates reduce the risk of femur neck fractures. After 3-5 years of bisphosphonate therapy, a possible relationship with fractures of the femur shaft has been observed, although a direct causal effect has not been proven. If bisphosphonates are used for periods more that 3-5 years, the number of prevented femur neck fractures still far outnumbers the possible AFFs caused. 2. Unique pharmacokinetics of the bisphosphonates Bisphosphonates are tightly bound to bone with residual efficacy up to 3 years or longer after cessation of therapy. Zoledronic acid, (iv) is bound more tightly to bone than alendronate, which in turn is more highly bound than risedronate and ibandronate, Dr de Villiers noted. In terms of length of alendronate therapy, the FLEX trial 25 showed that alendronate may be discontinued after 5 years, except for those patients at high risk of vertebral fractures who should be continued for a further 5 years. The zoledronate extension trial suggested that after 3 years of treatment, a drug holiday of 3 years can be considered except in patients at risk of vertebral fracture. NOFSA guidelines provide a useful approach to length of bisphosphonate therapy (Table 1). 2 JANUARY 2015
3 Table 1. NOFSA Guidelines We recommend that treatment with BPs should continue for at least 5 years. Following 5 years of therapy, we suggest that a drug holiday be considered in those who are not at high fracture risk. In subjects with fractures or BMD that is still in the osteoporosis range (T-score -2.5), in those with ongoing risk factors, and in those whose BMD responded poorly while on treatment (e.g. BMD decreased markedly), treatment with a non-bp like strontium ranelate or teriparatide should be considered Menopausal hormone therapy and bone in 2014: have we completed a full circle?* KEY MESSAGES Estrogen and combined estrogen/progestogen therapies prevent the development of postmenopausal osteoporosis and osteoporosis-related fractures at both the spine and hip Although the Women s Health Initiative (WHI) investigators claimed that the risks of HT outweigh the benefits, these assertions were based on an illogical interpretation of the data and are unfounded The timing of hormone therapy (HT) is very important. HT should be prescribed during the therapeutic window of opportunity, before the age of 60 years and within 10 years of menopause. Estrogen-only HT is not associated with an increased risk of breast cancer for at least 10 years The increase in risk of breast cancer associated with combined HT is not clinically important if HT is used for less than 10 years and if started early after menopause HT is associated with an increased risk of deep vein thrombosis, but this increased risk is limited predominantly to the first year of treatment HT has additional benefits in postmenopausal women that are not shared by other bone-preserving treatments. These include fall prevention, reduction of vasomotor symptoms and prevention of urogenital atrophy In the younger postmenopausal woman, in addition to its wide range of benefits for symptom relief, estrogen (alone or in combined HT) should be considered a first-line option for both treatment of osteoporosis and fracture prevention. Overview of key developments in bone preservation In 1984, estrogen was considered first-line therapy in treatment and prevention of postmenopausal osteoporosis. It was previously known that using estrogen after oophorectomy, even if it was initiated 3 or 6 years after surgical sterilization, could prevent bone loss. 2 However, these results were based on metacarpal bone mineral content measurements using dual photon absorbtiometry and they were not conclusively confirmed until the early 1990s, with the development of Dual-Energy X-Ray absorptiometry (DEXA), which allowed accurate measurement of bone mineral density (BMD). 3 In 1996 the Postmenopausal Estrogen/ Progestogen Intervention (PEPI) randomised trial showed that the use of hormone therapy (HT) with conjugated equine estrogen (CEE)/ medroxyprogesterone acetate (MPA) at the time of menopause prevented menopauserelated bone loss at both the spine and the hip. 4 Although observational data suggested that HT would also reduce fractures, this had yet to be proven in a randomised controlled study. In contrast, the efficacy of alendronate, a bisphosphonate, in reducing the incidence of postmenopausal vertebral fractures was conclusively demonstrated in postmenopausal women with and *This presentation is based on the 8 th Pieter van Keep memorial lecture delivered by Dr De Villiers in September JANUARY
4 Earn 3 CPD points at Click on Accredited Education Programmes/CPD without pre-existing vertebral fractures (Fracture Intervention Trial: FIT; 1996 and FIT2;1998). 5,6 With this, interest in estrogen as a bone preserving agent began to wane. In contrast, the interest in alternative prophylactic treatments was strengthened by publication of similar results for another bisphosphonate, risedronate (VERT study) and the selective estrogen receptor modulator (SERM), raloxifene, in the MORE study in ,8 Consequent to this, it was speculated that raloxifene might be a suitable replacement for postmenopausal estrogen. However, raloxifene does not treat hot flushes, but rather increases their intensity, and suggestions that it may be suitable for recently postmenopausal women proved to be unfounded, Dr de Villiers noted. Recombinant parathyroid hormone (teriparatide) was introduced in It was the first available anabolic agent and also had evidence of fracture reduction efficacy. 9 However, it is necessarily available only in injectable form, is expensive and efficacy is limited to months of treatment. Consequently, it did not become a popular choice of therapy. Evidence of the benefits of risedronate in reducing hip fracture published in 2001 strengthened the case for the use of bisphosphonates as the drugs of choice for prevention of postmenopausal fractures. 10 In 2002, the Women s Health Initiative (WHI) showed that estrogen reduced both hip and vertebral fractures in postmenopausal women; even in women at low risk of fracture. 11 This was important, because most other pharmacological agents do not have fracture-prevention data for both vertebral and non-vertebral fractures (including hip fractures). However, the WHI investigators further concluded that the positive effects of HT were outweighed by negative effects. Estrogen was downgraded to second-line therapy in the treatment of osteoporosis. 12 The introduction of strontium ranelate in 2004 was supported by robust vertebral fracture data in women with severe osteoporosis. 13 Although it was initially positioned for use in osteopenia, recent data and concerns over its cardiovascular safety have resulted in its use being restricted to women with severe osteoporosis. With the publication of the HORIZON study in 2007, the bisphosphonates were once again in the spotlight. In this 3-year trial, zoledronic acid was associated with a 70% reduction in risk of vertebral fractures and 41% reduction in risk of fractures at the hip. 14 The was achieved with a convenient dosing schedule of once yearly intravenous infusion. The benefits of postmenopausal estrogen were again confirmed in 2008 by the LIFT study showing that tibolone (a synthetic compound that is tissue-selectively metabolized to estrogen, progesterone and testosterone), reduced both vertebral and nonvertebral fractures. 15 However, although it was also associated with a reduction in breast and colon cancer, concern was expressed over an apparent increase in fatal stroke (but not in total stroke). In reality, the absolute number of fatal strokes in this study was small and the women in which they occurred were at high risk before treatment, so the actual clinical significance of this finding is questionable, Dr de Villiers pointed out. In 2008, bazedoxifene (BZA), a SERM similar to raloxifene, was shown to significantly reduce the incidence of vertebral fractures in postmenopausal women with osteoporosis. 16 It is also a potent inhibitor of endometrial proliferation, and studies were initiated to investigate its utility in combination with CEE for management of vasomotor symptoms and bone preservation in postmenopausal women. These studies confirmed that this progestin-free combination provided effective symptom control, while improving BMD at both the spine and hip. 17,18 It has recently become available in USA and is indicated for management of menopausal symptoms and prevention of osteoporosis. Fracture data is not yet available. The therapeutic options for osteoporotic women were further increased in 2009 with publication of favorable fracture data for denosumab. 19 Denosumab is the first biological drug available for fracture prevention (human monoclonal antibody against RANK ligand. Finally in 2013, the circle of trial evidence was completed, when 13-year data from the WHI was published, again renewing interest in the use of estrogen for bone health after menopause. Why did WHI lead to concerns about the safety of estrogen? The fracture data for estrogen in the WHI is actually very robust. In the combined CEE/MPA arm, the hazard ratios (HR) 4 JANUARY 2015
5 Figure 1. Age-adjusted incidence rates of specific fractures per 1000 women (40-69 years of age) by year. 20 (95% confidence intervals) for hip, clinical vertebral and non-vertebral fractures were 0.66 ( ); 0.66 ( ) and 0.77 ( ), respectively. In the estrogenonly arm, they were 0.61 ( ) for hip fracture, 0.62 ( ) for clinical vertebral fracture and 0.79 ( ) for total fractures. However, the investigators declared that these and other benefits were outweighed by adverse effects of HT. The ensuing black box warning by the Federal Drug Administration (FDA) in the USA, confining HT to the treatment of vasomotor symptoms and the prevention of osteoporosis and the relegation of HT to second line treatment of osteoporosis, by the European regulatory agencies placed significant limitations on the use of HT, despite the positive data. It is notable that after 2002, in the USA, where most doctors stopped using HT for postmenopausal bone health, epidemiological studies demonstrated a significant increase in the incidence of fractures among perimenopausal and postmenopausal women. (Figure 1). 20 It is important to understand how the WHI investigators reached their conclusions on the risk/benefit ratio of HT. They based their estimation on a model called the global index (Table 2), where selected endpoints are grouped together as being of equal significance and judged on numerical occurrence, disregarding individual statistical significance of difference to placebo. 21 This approach, to combine HRs for a widely heterogeneous set of outcomes so that summation of good effects may be subtracted from summation of bad effects to produce a single HR that determines a risk to benefit ratio, is clearly irrational, Dr de Villiers noted. Furthermore, although vertebral fracture data and data for all non-vertebral fractures were reported in the study results, Table 2. Global Index: WHI 21 More or less cases per patients Combined CEE/MPA CEE alone Coronary heart disease +6-3 Stroke Pulmonary embolus Breast cancer +9-7 Endometrial cancer -1 Not applicable Colorectal cancer Hip fracture -6-6 All-cause mortality Total JANUARY
6 We accept today that in the younger woman below the age of 60 years and within 10 years of menopause benfits of HT are more likely to outweigh any risk, irrespective of the indication. these were excluded from the global index so that the analysis included only findings for hip fracture. Routine X-rays were not done to record morphometric fractures, so the actual effect of estrogen on vertebral fractures would have been significantly understated. Baseline data indicates that the women participating in WHI were at low risk for fractures. The average T-score at the spine was In reality, although only deep vein thrombosis (DVT) and stroke were significant risks associated with HT, when they were grouped with all the other adverse outcomes, the investigator s global index indicated that, in total, risks outweighed benefits. There are additional problems with the analysis of risk vs benefits in WHI. During the study period, there were high rates of discontinuation in the active treatment arm (42%) and cross-over to active treatment in the placebo arm (10.7%), leading to detection bias and confounding, and questioning the use of an intention-to-treat analyses. Furthermore, the mean age of women included in WHI was 63 years, older than those in the therapeutic window of opportunity for whom HT would normally be recommended. 22 If the global index is re-analysed to include prevalent DVT and all fractures, it can be seen that clearly the benefits of HT actually outweigh the risks the converse of investigators findings (Table 3). Correct selection of patients for HT and bone preserving therapies The benefits of HT are most likely to outweigh risks in the younger patient below age of sixty or within 10 years of menopause, whatever the indication. We also learned from the WHI that combined estrogen and progestin therapy should never be initiated after age of 70 years as this was associated with cognitive decline. We thus know that HT is the preferred drug for the prevention of osteoporosis in the younger patient. What about the women between the age of at risk of fracture? It must be understood that the window of opputunity (50-60 years) was defined from a cardiovascular point of view and the peak time for occurrence of hot flushes. In other words, HT will not protect against coronary aretrial disease if initiated outside this window, but there will also not be significant adverse cardiovascular outcomes. Bone protection however is present at all ages. It is thus logical that HT can be considered for bone protection in the women between ages years, but the following principles need to be followed: Use the lowest effective dose In the hysterectomized women, use estrogen alone If at risk of DVT, use the transdermal route of application If combination therapy cannot be avoided, progesterone or its most natural equivalent should be used at the lowest effective dose, and MPA should be avoided. An alternative option is to use an intrauterine progesterone-containing device (Mirena ) with low dose estrogen. How long can we use HT? This question is very pertinent, as the benficial effect of HT on bone is most likely lost soon after cessation of therapy. Table 3. Bone-centric Global Index: WHI 21 More or less cases per patients Earn 3 CPD points at Click on Accredited Education Programmes/CPD Combined CEE/MPA CEE alone Coronary heart disease +6-3 Stroke Pulmonary embolus Breast cancer +9-7 Endometrial cancer -1 Not applicable Colorectal cancer Hip fracture -6-6 All-cause mortality Total All fractures DVT Total JANUARY 2015
7 The age limitations as discussed before pertain only to the initiation of therapy. The global consensus statement does not place any mandatary limitation on the length of treatment. As a matter of fact most of the possible adverse events associated with use of HT actually decrease, the longer treatment is used, with the exception of breast cancer However, the effects of HT on breast cancer are poorly understood. In the estrogen-only arm of WHI the risk of breast cancer was reduced, even after 13 years of follow-up. Progestogens, on the other hand, have a cancer-promoting effect and use beyond 7 years may be associated with an increase in risk. This effect may be diluted by using the most natural progestogen (micronized progestogen) or by combining estrogen with bazedoxifene, which would probably eliminate the increased risk of breast cancer altogether. It should further be kept in mind that the risk of breast cancer is very small and is reversed after cessation of therapy. Menopause treatment guidelines recommend that the dose and duration of HT should be consistent with goals of therapy and safety issues, and should be individualised. 22 Comparison of HT to other available bone drugs Although there are no head-to-head studies, the magnitude of fracture risk reduction with HT is comparable to that demonstrated in clinical studies of other bone-specific medications (Fig 2). 23 However, in comparison to these other treatments, estrogen is the only agent with proven efficacy in primary analysis of a large randomised controlled clinical study to show protection against all types of osteoporotic fractures (Table 4). This is especially important in the osteopenic patient at risk of fracture. All treatments are associated with the potential for side effects and, in addition to the effect on fracture risk, these need to be considered before choosing an appropriate therapy for the individual patient (Table 4). HT has been shown to be associated with an increased risk of venous thromboembolic episodes in most studies. However, this is mostly limited to the first year of treatment, and is dependent on dose, age, body mass index and other risk factors. Transdermal HT is not associated with an increased risk of DVT. The effects of HT on stroke varies between different studies but was increased in the WHI study. This may be a specific effect of the dose of estrogen (not shown with lower dose in other studies) and/or the use of MPA. In comparison to other drugs, estrogen is also associated with a number of additional benefits. These include fall prevention, reduction of vasomotor symptoms and prevention of urogenital atrophy. This *with previous vertebral fracture(s) ** without previous vertebral fractures RLX: raloxifene; ALN: alendronate; RIS: risedronate; CT: calcitonin Figure 2. Comparison of the magnitude of fracture prevention with different bonepreserving agents. 23 JANUARY
8 Table 4. Comparison of fracture prevention and treatment-related side effects Treatment Fracture type Potential side effects Vertebral Nonvertebral Hip Estrogen yes yes yes Yes Raloxifene yes no no No data Bazedoxifene yes no Strontium ranelate yes yes Only if at high risk Only if at high risk Bisphosphonate yes yes yes No Osteopenia: prospective RCT No data Yes Denosumab yes yes yes No data DVT, stroke, breast cancer DVT, stroke DVT, stroke, DRESS Osteonecrosis of the jaw, atypical femur fracture, atrial fibrillation Osteonecrosis of the jaw (?), atypical femur fracture (?) Teriparatide yes No data No data No data Osteosarcoma (?) RCT: randomised controlled clinical trial; DRESS: drug reaction with eosinophilia and systemic symptoms; DVT: deep vein thrombosis latter benefit is of considerable significance to improving the quality of life of the postmenopausal woman and on its own may justify the selection of estrogen as a first choice therapy in the symptomatic patient at risk of fracture. Have we completed the full circle? Thirty years after its recognition as a useful treatment to preserve bone in surgically sterilised and ageing women, a considerable volume of clinical trials bear testimony to the usefulness of estrogen after menopause. In 2014, in the younger postmenopausal woman, in addition to its wide range of benefits for symptom relief, estrogen should be considered a first-line option for both treatment of osteoporosis and fracture prevention. In conclusion, Dr de Villiers noted that these recommendations remind us that: New drugs are not better all of the time. Old drugs are better some of the time. Our treatment recommendations have indeed come full circle. Need for Vit D supplementation in South African populations According to the US Institute of Medicine, Vit D deficiency is defined at serum 25- hydroxyvitamin D levels of <12ng/ml or <30nmol/l A recent study of Vit D deficiency in African-origin populations at varying latitudes has shown decreasing Vit D levels from the equator southwards/northwards 26 In one study 30% of the US African adult population was Vit D deficient and 40% Vit D insufficient. Among Africans in Cape Town the prevalence of Vit D deficiency was 7% and Vit D insufficiency was 30% A study among black females in Johannesburg 27 has shown Vit D deficiency in 5% of women (mean age 42 years). However almost one-third of the Asian females assessed were vitamin D deficient. Prof John Pettifor (Wits) noted that the level of Vit D deficiency in Indian females warrants universal Vit D supplementation in this group of women. 8 JANUARY 2015
9 References: 1. De Villiers TJ. Estrogen and bone: have we completed a full circle? Climacteric 2014; 17(2): Lindsay R, Hart DM. Effect of estrogens on postmenopausal bone loss. Br Med J 1977; 2: Lindsay R. Estrogens, bone mass and osteoporotic fracture. Am J Med 1991; 91(5B): 10S-13S. 4. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 276: Black DM, Cummings SR, Karpf D B, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280(24): Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282(7): Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New Engl J Med 2001; 344(5): Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women s Health Initiative randomized controlled trial. JAMA 2002; 288: Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women s Health Initiative randomized trial. JAMA 2003; 290: Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: Black D M, Delmas P D, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 359: Silverman S L, Christiansen C, Genant H K, et al. Efficacy of bazedoxifene in reducing new vertebral fracture rate in postmenopausal women with osteoporosis: results of a 3-year randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008; 12: Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99(2): E Mirkin S, Komm B, Pickar JH. Conjugated estrogen/ bazedoxifene tablets for the treatment of moderateto-severe vasomotor symptoms associated with menopause. Women s Health (Lond Engl) 2014; 10(2): Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: Islam S, Liu Q, Chine A, Helzner E. Trend in incidence of osteoporosis-related fractures among 40- to 69-year-old women: analysis of a large insurance claims database, Menopause 2009; 16(1): Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women s Health Initiative randomized trials. JAMA 2013; 310: de Villiers TJ, Gass MLS, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013; 16: Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359(9322): Schilder J, Koeppen V, Aspenburg P, Michaelsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014; 371: Ensrud KE et al. Randomisation trial of alendronate therapy continuation in women with low BMD. Results from the Fracture intervention Trial long term extension group. J Bone Mineral Res 2004;19(8): Duazo-Arvizu RA, Camacho P, Bovet P, et al. 25-Hydroxyvitamin D in African-origin populations at varying latitudes challenges the construct of a physiologic norm. Am J Clin Nutr 2014; 100(3): George JA et al. The association between body composition, 25 (OH)D, PTH and bone mineral density in black African and Asian Indian population groups. J Clin Endocrinol Metab 2014; 99(6): CPD How to earn CPD points online: Visit click on Accredited Educational Programmes/CPD, click on registration, then answer the relevant questionnaire. Your CPD certificate will be ed to you shortly. Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com JANUARY
SERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationOSTEOPOROSIS: PREVENTION AND MANAGEMENT
OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationSelective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence
Review: Clinical Trial Outcomes Selective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence Clin. Invest. (2011) 1(5), 719 724 The ideal selective estrogen
More informationControversies in Osteoporosis Management
Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute
More informationGynecologists are first-line providers for
Update OSTEOPOROSIS A new agent, and new understandings of old drugs, top the year s developments in bone health Steven R. Goldstein, MD Dr. Goldstein is Professor, Department of Obstetrics and Gynecology,
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationPage 1. Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018? Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco What s
More informationDiagnosis and Treatment of Osteoporosis: What s New and Controversial in ? What s New in Osteoporosis
Diagnosis and Treatment of Osteoporosis: What s New and Controversial in 2018-19? What s New in Osteoporosis The crisis in treatment and compliance Douglas C. Bauer, MD Professor of Medicine and Epidemiology
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationLong-term Osteoporosis Therapy What To Do After 5 Years?
Long-term Osteoporosis Therapy What To Do After 5 Years? Developing a Long-term Management Plan North American Menopause Society Philadelphia, PA October 11, 2017 Michael R. McClung, MD, FACP Institute
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationThis house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against
This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical
More informationPage 1. New Developments in Osteoporosis. What s New in Osteoporosis
New Developments in Osteoporosis Eliseo J. Pérez-Stable MD Professor of Medicine Division of General Internal Medicine Department of Medicine July 4, 2013 Declaration of full disclosure: No conflict of
More informationOsteoporosis Agents Drug Class Prior Authorization Protocol
Osteoporosis Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of
More informationEndocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni. Hot topics in osteoporosis. How long to treat
Endocrine Unit and Chair of Endocrinology Director Prof. Manuela Simoni Hot topics in osteoporosis How long to treat Dott. Bruno Madeo bruno.madeo@unimore.it www.endocrinologia.unimore.it/on-line/home.html
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationCalcium, Vitamin D and Bisphosphonates: Disclosures. Benefits, Risks and Drug Holiday. Calcium YES or NO? Calcium Bad News!!
Calcium, Vitamin D and Bisphosphonates: Benefits, Risks and Drug Holiday Disclosures I am disclosing financial relationships as follows: Global Advisory Boards: Amgen, Lilly, Merck, Novartis Research grants:
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationHorizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre
Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationAn Update on Osteoporosis Treatments
An Update on Osteoporosis Treatments Dr Mike Stone University Hospital Llandough Treatments for osteoporosis Calcium and vitamin D HRT Raloxifene Etidronate Alendronate Risedronate Ibandronate (oral and
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationSummary of the risk management plan by product
Summary of the risk management plan by product 1 Elements for summary tables in the EPAR 1.1 Summary table of Safety concerns Summary of safety concerns Important identified risks Important potential risks
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationDoes raloxifene (Evista) prevent fractures in postmenopausal women with osteoporosis?
FPIN's Clinical Inquiries Raloxifene for Prevention of Osteoporotic Fractures Clinical Inquiries provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationEffective Health Care
Number 12 Effective Health Care Comparative Effectiveness of Treatments To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis Executive Summary Background Osteoporosis is a systemic
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationDifferentiating Pharmacological Therapies for Osteoporosis
Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking
More information2017 Santa Fe Bone Symposium McClung
217 Santa Fe Bone Symposium Insights into the Use of Anti-remodeling and Anabolic Agents for Osteoporosis Developing a Long-term Management Plan Michael R., MD, FACP Oregon Osteoporosis Center Portland,
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationOsteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital
Osteoporosis: Are your bones at risk of fracturing? Rachel Wallwork, MD Internal medicine resident Massachusetts General Hospital What is Osteoporosis? Osteoporosis causes bones to lose density, become
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationPage 1. Current and Emerging Strategies What s New in Osteoporosis. Osteoporosis. What is Osteoporosis? Traditional Risk Factors for Fracture
Current and Emerging Strategies for Osteoporosis What s New in Osteoporosis Risk stratification Douglas C. Bauer, MD University of California, San Francisco Under recognition and poor compliance New potential
More informationPostmenopausal osteoporosis is a systemic
OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility
More informationBenton Franklin County Medical Society 31st Annual CME Seminar
Management of Current HT/ET and SERM Recommendations Benton Franklin County Medical Society 31st Annual CME Seminar February 21, 2015 Kennewick, Washington Spokane steoporosis Dr. Lynn Kohlmeier Lynn Kohlmeier,
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationUpdate on Osteoporosis 2016
WELCOME! Update on Osteoporosis 2016 Jennifer J. Kelly, D.O., F.A.C.E. Associate Professor of Medicine Division of Endocrinology, Diabetes and Metabolism Upstate Medical University Director of the Clinical
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.
4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationOsteoporosis Evaluation and Treatment
Osteoporosis Evaluation and Treatment Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism October 28, 2011 No conflicts of interest Objectives Explain when to initiate
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationTherapy and Sexual Health
Menopausal hormone therapy and sexual health Earn 3 CPD Points online Menopausal Hormone Therapy and Sexual Health Key messages Dr Tobie De Villiers Consultant Gynaecologist Panorama MediClinic Department
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationNew therapies for osteoporosis. Dr.Shobhana Mohandas.MD.DGO.FICOG. Sun Medical centre, Thrissur, Kerala.
New therapies for osteoporosis Dr.Shobhana Mohandas.MD.DGO.FICOG. Sun Medical centre, Thrissur, Kerala. Osteoclastic resorption Sema 4 D Plexin B1 from osteo TGF-β1, and IGF-1 Osteoblast Migration Osteoblast
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP
More informationChau Nguyen, D.O. Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences
Chau Nguyen, D.O Rheumatologist Clinical Assistant Professor of Internal Medicine at Western University of Health Sciences I do not have any relationship with the manufacturer of any commercial products
More informationJohn J. Wolf, DO Family Medicine
John J. Wolf, DO Family Medicine Objectives: 1. Review incidence & Risk of Osteoporosis 2.Review indications for testing 3.Review current pharmacologic & Non pharmacologic Tx options 4.Understand & Utilize
More informationFocusing on the Patient: Diagnosis and Management of Osteoporosis
Focusing on the Patient: Diagnosis and Management of Osteoporosis Learning Objectives After participating in this educational activity, participants should be able to: 1. Apply updated guidelines to assess
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationRefracture Prevention The Role of Primary Care
MonashHealth Refracture Prevention The Role of Primary Care Professor Peter R Ebeling AO MBBS MD FRACP Head, Department of Medicine School for Clinical Sciences Monash Health Translation Precinct Monash
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationClinical Specialist Statement Template
Clinical Specialist Statement Template Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can
More informationOsteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians
More informationPage 1
Osteoporosis Osteoporosis is a condition characterised by weakened bones that fracture easily. After menopause many women are at risk of developing osteoporosis. Peak bone mass is usually reached during
More informationEveryone knows 1/15/2018. Does Osteopenia Warrant Treatment? Osteoporosis Prevention: Is it Ever Warranted?
/5/8 Wednesday, October, 7 : AM :5 AM Osteoporosis Prevention: Is it Ever Warranted? James A. Simon, MD, CCD, NCMP, IF, FACOG Clinical Professor Department of Ob/Gyn George Washington University Washington,
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationCurrent and Emerging Approaches for Osteoporosis
Current and Emerging Approaches for Osteoporosis Douglas C. Bauer, MD Professor of Medicine and Epidemiology & Biostatistics University of California, San Francisco No Disclosures What s New in Osteoporosis
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationSummary. Background. Diagnosis
March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationA response by Servier to the Statement of Reasons provided by NICE
A response by Servier to the Statement of Reasons provided by NICE Servier gratefully acknowledges the Statement of Reasons document from NICE, and is pleased to provide information to assist NICE in its
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationAN OVERVIEW of TREATMENT: WHO and WHEN to TREAT
AN OVERVIEW of TREATMENT: WHO and WHEN to TREAT Dolores Shoback, MD Professor of Medicine, UCSF San Francisco VA Medical Center July 16, 21 ~ QUESTIONS ~ Who should receive therapy to prevent fractures?
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More information